Work

Liver Transplantation Rates in Patients with Hepatorenal Syndrome-Acute Kidney Injury Treated with Terlipressin: Effect of Selecting an Appropriate Patient Population

Year: 2025

Type: article

Abstract: Purpose: Hepatorenal syndrome-acute kidney injury (HRS-AKI) occurs in patients (pts) with decompensated cirrhosis and ascites. A liver transplant (LT) is definitive treatment for the underlying disease. Terlipressin (terli) can reverse HRS-AKI; however, a resulting decrease in serum creatinine (SCr) may reduce MELD score and be perceived to negatively affect LT prioritization. A strategy, reflected in the FDA label, identifies pts who have a more favorable risk-to-benefit profile with terli; this population is referred to as the “label-specific population (LSP)” and includes pts with acute-on-chronic liver failure (ACLF) grade <3, SCr <5 mg/dL, and MELD score <35 (if listed for LT).

Source: American Journal of Transplantation

DOI: 10.1016/j.ajt.2025.07.1098

Authors: H. Vargas, P. Martin, S. Sigal, R. Wu, S. Cardoza, S. Pappas

Institutions: Mayo Clinic, University of Miami, NYU Grossman Long Island School of Medicine

Language: English

Topic: Liver Disease and Transplantation

Subfield: Hepatology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $4,300